Want to join the conversation?
$BMY said its sales for Eliquis were $602MM in 4Q15, which more than doubled from 4Q14. Eliquis is the number one NOAC (novel anticoagulant) in new-to-brand patient share in cardiology across 12 markets around the world. The company continues to see strong demand trends from key markets such as the US, Germany and Japan.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)